DSGN Stock Overview
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Design Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.27 |
| 52 Week High | US$26.30 |
| 52 Week Low | US$6.94 |
| Beta | 0 |
| 1 Month Change | -19.71% |
| 3 Month Change | -48.63% |
| 1 Year Change | -33.89% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -80.07% |
Recent News & Updates
Recent updates
Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
Oct 25
We're Not Very Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Rate
Jul 02Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
Mar 18Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
Dec 03Here's Why We're Not Too Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Situation
Aug 18Shareholder Returns
| DSGN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -7.3% | 0.8% | 2.8% |
| 1Y | -33.9% | 7.1% | -9.2% |
Return vs Industry: DSGN underperformed the US Biotechs industry which returned 7.1% over the past year.
Return vs Market: DSGN underperformed the US Market which returned -9.7% over the past year.
Price Volatility
| DSGN volatility | |
|---|---|
| DSGN Average Weekly Movement | 14.2% |
| Biotechs Industry Average Movement | 12.2% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: DSGN is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: DSGN's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 56 | João Siffert | https://www.designtx.com |
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company’s portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy.
Design Therapeutics, Inc. Fundamentals Summary
| DSGN fundamental statistics | |
|---|---|
| Market Cap | US$461.80m |
| Earnings (TTM) | -US$57.03m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-8.1x
P/E RatioIs DSGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DSGN income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$27.07m |
| Gross Profit | -US$27.07m |
| Other Expenses | US$29.96m |
| Earnings | -US$57.03m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.02 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did DSGN perform over the long term?
See historical performance and comparison